Trial · NCT07907302
Strength and Dual-Task on Sarcopenia in People With Parkinson's Disease
NCT07907302, Not applicable, Recruiting, University of Valencia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Strength and Dual-Task on Sarcopenia in People With Parkinson's Disease. Trials, record NCT07907302. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07907302
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Strength and Dual-Task on Sarcopenia in People With Parkinson's Disease
- NCT number
- NCT07907302
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 60 participants, estimated
- Lead sponsor
- University of Valencia
- Conditions
- PARKINSON DISEASE (Disorder), Parkinsonism or Parkinson's Disease Nos
- Interventions
Nutricional Education and General Exercise Guidelines, Progressive Resistance Training With Cognitive Dual-Task Training, Progressive Resistance Training With Cognitive Dual-Task and Inestability Training
- First posted
- 2026-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Handgrip Strength | Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2). | Handgrip strength will be assessed using handgrip dynamometry as a measure of muscle strength within the EWGSOP2 sarcopenia assessment framework. Higher values indicate greater muscle strength. |
| Primary | Physical Performance - Short Physical Performance Battery (SPPB) | Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2). | Physical performance will be assessed using the Short Physical Performance Battery (SPPB), which evaluates balance, gait speed, and lower-limb functional performance. The total score ranges from 0 to 12 points, with higher scores indicating better physical performance. |
| Primary | Body Composition -Body fat (%) | Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2). | It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in %. |
| Primary | Body Composition -Body fat (kg) | Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2). | It will be assessed assessed using bioelectrical impedance analysis (BIA), measured in kg. |
| Primary | Body Composition -Lean mass (kg) | Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2). | It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in kg. |
| Primary | Body Composition -Lean mass (%) | Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2). | It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in %. |
| Primary | Body Composition -body water(%) | Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2). | It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in %. |
| Primary | Body Composition -body water(kg) | Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2). | It will be assessed assessed using bioelectrical impedance analysis (BIA) , measured in kg. |
| Secondary | Functional Mobility - Timed Up and Go (TUG) | Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2). | Functional mobility will be assessed using the Timed Up and Go (TUG) test. The time required to stand up from a chair, walk 3 meters, turn, walk back, and sit down will be recorded in seconds. Lower completion times indicate better functional mobility. |
| Secondary | Sarcopenia Risk - SARC-F | Baseline (T0), immediately after the 12-week intervention (T1), and 4 weeks after intervention completion (T2). | Sarcopenia risk will be assessed using the SARC-F questionnaire, which evaluates strength, assistance with walking, rising from a chair, climbing stairs, and falls. The total score ranges from 0 to 10 points, with higher scores indicating greater risk of sarcopenia. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07907302
GET https://conductscience.org/api/trials/v1/NCT07907302/registered